|
|
| (One intermediate revision not shown.) |
| Line 3: |
Line 3: |
| | <StructureSection load='4zjs' size='340' side='right'caption='[[4zjs]], [[Resolution|resolution]] 2.23Å' scene=''> | | <StructureSection load='4zjs' size='340' side='right'caption='[[4zjs]], [[Resolution|resolution]] 2.23Å' scene=''> |
| | == Structural highlights == | | == Structural highlights == |
| - | <table><tr><td colspan='2'>[[4zjs]] is a 5 chain structure with sequence from [http://en.wikipedia.org/wiki/Aplca Aplca]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4ZJS OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4ZJS FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[4zjs]] is a 5 chain structure with sequence from [https://en.wikipedia.org/wiki/Aplysia_californica Aplysia californica] and [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4ZJS OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4ZJS FirstGlance]. <br> |
| - | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=4P0:1-[(1R,6R)-9-AZABICYCLO[4.2.1]NON-2-EN-2-YL]ETHANONE'>4P0</scene></td></tr> | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.2301Å</td></tr> |
| - | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">CHRNA1, ACHRA, CHNRA ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=6500 APLCA])</td></tr> | + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=4P0:1-[(1R,6R)-9-AZABICYCLO[4.2.1]NON-2-EN-2-YL]ETHANONE'>4P0</scene></td></tr> |
| - | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4zjs FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4zjs OCA], [http://pdbe.org/4zjs PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4zjs RCSB], [http://www.ebi.ac.uk/pdbsum/4zjs PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4zjs ProSAT]</span></td></tr> | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4zjs FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4zjs OCA], [https://pdbe.org/4zjs PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4zjs RCSB], [https://www.ebi.ac.uk/pdbsum/4zjs PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4zjs ProSAT]</span></td></tr> |
| | </table> | | </table> |
| | == Disease == | | == Disease == |
| - | [[http://www.uniprot.org/uniprot/ACHA_HUMAN ACHA_HUMAN]] Postsynaptic congenital myasthenic syndromes;Lethal multiple pterygium syndrome. The disease is caused by mutations affecting the gene represented in this entry. The alpha subunit is the main focus for antibody binding in myasthenia gravis. Myasthenia gravis is characterized by sporadic muscular fatigability and weakness, occurring chiefly in muscles innervated by cranial nerves, and characteristically improved by cholinesterase-inhibiting drugs. The disease is caused by mutations affecting the gene represented in this entry. The disease is caused by mutations affecting the gene represented in this entry. | + | [https://www.uniprot.org/uniprot/ACHA_HUMAN ACHA_HUMAN] Postsynaptic congenital myasthenic syndromes;Lethal multiple pterygium syndrome. The disease is caused by mutations affecting the gene represented in this entry. The alpha subunit is the main focus for antibody binding in myasthenia gravis. Myasthenia gravis is characterized by sporadic muscular fatigability and weakness, occurring chiefly in muscles innervated by cranial nerves, and characteristically improved by cholinesterase-inhibiting drugs. The disease is caused by mutations affecting the gene represented in this entry. The disease is caused by mutations affecting the gene represented in this entry. |
| | == Function == | | == Function == |
| - | [[http://www.uniprot.org/uniprot/ACHA_HUMAN ACHA_HUMAN]] After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. | + | [https://www.uniprot.org/uniprot/Q8WSF8_APLCA Q8WSF8_APLCA] [https://www.uniprot.org/uniprot/ACHA_HUMAN ACHA_HUMAN] After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. |
| | <div style="background-color:#fffaf0;"> | | <div style="background-color:#fffaf0;"> |
| | == Publication Abstract from PubMed == | | == Publication Abstract from PubMed == |
| Line 21: |
Line 21: |
| | </div> | | </div> |
| | <div class="pdbe-citations 4zjs" style="background-color:#fffaf0;"></div> | | <div class="pdbe-citations 4zjs" style="background-color:#fffaf0;"></div> |
| | + | |
| | + | ==See Also== |
| | + | *[[Acetylcholine binding protein 3D structures|Acetylcholine binding protein 3D structures]] |
| | == References == | | == References == |
| | <references/> | | <references/> |
| | __TOC__ | | __TOC__ |
| | </StructureSection> | | </StructureSection> |
| - | [[Category: Aplca]] | + | [[Category: Aplysia californica]] |
| | + | [[Category: Homo sapiens]] |
| | [[Category: Large Structures]] | | [[Category: Large Structures]] |
| - | [[Category: Bobango, J]] | + | [[Category: Bobango J]] |
| - | [[Category: Lindsatrom, J]] | + | [[Category: Lindsatrom J]] |
| - | [[Category: Luo, J]] | + | [[Category: Luo J]] |
| - | [[Category: Park, J F]] | + | [[Category: Park JF]] |
| - | [[Category: Talley, T T]] | + | [[Category: Talley TT]] |
| - | [[Category: Taylor, P]] | + | [[Category: Taylor P]] |
| - | [[Category: Wu, J]] | + | [[Category: Wu J]] |
| - | [[Category: Acetylcholine]]
| + | |
| - | [[Category: Anatoxin-a]]
| + | |
| - | [[Category: Immune system]]
| + | |
| - | [[Category: Nicotinic]]
| + | |
| - | [[Category: Receptor]]
| + | |
| Structural highlights
Disease
ACHA_HUMAN Postsynaptic congenital myasthenic syndromes;Lethal multiple pterygium syndrome. The disease is caused by mutations affecting the gene represented in this entry. The alpha subunit is the main focus for antibody binding in myasthenia gravis. Myasthenia gravis is characterized by sporadic muscular fatigability and weakness, occurring chiefly in muscles innervated by cranial nerves, and characteristically improved by cholinesterase-inhibiting drugs. The disease is caused by mutations affecting the gene represented in this entry. The disease is caused by mutations affecting the gene represented in this entry.
Function
Q8WSF8_APLCA ACHA_HUMAN After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Publication Abstract from PubMed
The main immunogenic region (MIR) is a conformation-dependent region at the extracellular apex of alpha1 subunits of muscle nicotinic acetylcholine receptor (AChR) that is the target of half or more of the autoantibodies to muscle AChRs in human myasthenia gravis and rat experimental autoimmune myasthenia gravis. By making chimeras of human alpha1 subunits with alpha7 subunits, both MIR epitopes recognized by rat mAbs and by the patient-derived human mAb 637 to the MIR were determined to consist of two discontiguous sequences, which are adjacent only in the native conformation. The MIR, including loop alpha1 67-76 in combination with the N-terminal alpha helix alpha1 1-14, conferred high-affinity binding for most rat mAbs to the MIR. However, an additional sequence corresponding to alpha1 15-32 was required for high-affinity binding of human mAb 637. A water soluble chimera of Aplysia acetylcholine binding protein with the same alpha1 MIR sequences substituted was recognized by a majority of human, feline, and canine myasthenia gravis sera. The presence of the alpha1 MIR sequences in alpha1/alpha7 chimeras greatly promoted AChR expression and significantly altered the sensitivity to activation. This reveals a structural and functional, as well as antigenic, significance of the MIR.
Main immunogenic region structure promotes binding of conformation-dependent myasthenia gravis autoantibodies, nicotinic acetylcholine receptor conformation maturation, and agonist sensitivity.,Luo J, Taylor P, Losen M, de Baets MH, Shelton GD, Lindstrom J J Neurosci. 2009 Nov 4;29(44):13898-908. doi: 10.1523/JNEUROSCI.2833-09.2009. PMID:19890000[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
See Also
References
- ↑ Luo J, Taylor P, Losen M, de Baets MH, Shelton GD, Lindstrom J. Main immunogenic region structure promotes binding of conformation-dependent myasthenia gravis autoantibodies, nicotinic acetylcholine receptor conformation maturation, and agonist sensitivity. J Neurosci. 2009 Nov 4;29(44):13898-908. doi: 10.1523/JNEUROSCI.2833-09.2009. PMID:19890000 doi:http://dx.doi.org/10.1523/JNEUROSCI.2833-09.2009
|
